Bill > HR1476

This bill, known as the PLASMA Act (Preserving Life-saving Access to Specialty Medicines in America Act), modifies Medicare Part D prescription drug coverage for plasma-derived products, which are biological products derived from human whole blood or plasma. The bill establishes a gradual phase-in of discounted pricing for these products from 2026 to 2032, with different discount percentages based on whether a Medicare beneficiary has reached their annual out-of-pocket drug spending threshold. For beneficiaries who have not reached the threshold, the discounts will range from 99% in 2026 to 90% in 2030 and subsequent years. For beneficiaries who have reached the threshold, the discounts will start at 99% in 2026, gradually decrease to 90% by 2030, then further reduce to 80% by 2032. The bill specifically excludes certain drugs dispensed to low-income subsidy beneficiaries and drugs from specified small manufacturers from these new discount calculations. This phased approach aims to provide more affordable access to plasma-derived medications while allowing manufacturers a gradual transition to lower pricing.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/1476/all-info